Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Pharma-Bio Serv's ebitda for the twelve months ending Jul 31, 2026 was -$97.01K. For fiscal 2025 it was -$577.80K. The highest annual figure on record is $6.42M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$577.80K | – |
| FY2024 | Oct 31, 2024 | -$1.26M | -208.5% |
| FY2023 | Oct 31, 2023 | $1.17M | -4.9% |
| FY2022 | Oct 31, 2022 | $1.23M | – |
| FY2021 | Oct 31, 2021 | -$3.78M | -263.5% |
| FY2020 | Oct 31, 2020 | $2.31M | +28.7% |
| FY2019 | Oct 31, 2019 | $1.80M | – |
| FY2018 | Oct 31, 2018 | -$1.19M | – |
| FY2017 | Oct 31, 2017 | -$670.14K | -403.5% |
| FY2016 | Oct 31, 2016 | $220.80K | -89.7% |
| FY2015 | Oct 31, 2015 | $2.14M | -34.0% |
| FY2014 | Oct 31, 2014 | $3.24M | -49.5% |
| FY2013 | Oct 31, 2013 | $6.42M | +6.0% |
| FY2012 | Oct 31, 2012 | $6.06M | +60.5% |
| FY2011 | Oct 31, 2011 | $3.77M | +305.0% |
| FY2010 | Oct 31, 2010 | $931.60K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$58.13K | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $158.32K | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$79.74K | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$117.46K | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$298.13K | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$79.46K | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$82.75K | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$148.20K | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$377.19K | -179.9% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$307.87K | -178.3% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$431.01K | -225.0% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$44.37K | -104.2% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $471.87K | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $393.25K | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $344.76K | -9.0% |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | $1.04M | +268.2% |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$382.47K | -212.3% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -$4.78M | -2878.3% |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $378.67K | -54.9% |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | $283.61K | -61.8% |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $340.55K | -38.9% |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | $172.18K | -61.9% |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | $839.89K | +117.7% |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | $741.96K | +48.8% |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | $557.79K | +12.0% |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | $451.85K | -10.9% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | $385.82K | -48.0% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | $498.77K | +3880.3% |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | $497.86K | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $507.31K | – |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $742.30K | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | $12.53K | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -$2.45M | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -$65.66K | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$106.03K | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$223.92K | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$274.54K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$368.26K | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -$43.11K | – |
See a number that looks wrong?